Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib

Trial Profile

Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological malignancies; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Dec 2009 to 1 Jan 2018.
    • 16 Sep 2013 Planned number of patients changed from 55 to 61 as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Planned number of patients changed from 62 to 55, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top